Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

-Amended Agreement Accelerates Expected Timing of Final Analysis by One Year While Maintaining Comparable Powering of Interim and Final Results- -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM

ET-

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amended Special Protocol Assessment (SPA) for the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the IMPACT trial to amend the Biologics License Application (BLA) for licensure of PROVENGE.

The amended SPA accelerates the expected timing of the final IMPACT results by approximately one year while maintaining comparable powering of the study's interim and final results. By increasing the number of events and decreasing the alpha (false positive error) spending function for the interim analysis, the Company is able to reduce the number of events for the final analysis (from 360 to 304) and still maintain a comparable statistical power for both the interim and final analyses. Interim results are still expected in the second half of 2008; however, final results are now expected in the second half of 2009 rather than 2010.

Based on the statistical plan in the amended SPA, if the treatment effect at the interim analysis for the IMPACT trial is consistent with the integrated results of the previous two completed pha
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
(Date:10/30/2014)... BASKING RIDGE, N.J. , Oct. 30, 2014 /PRNewswire/ ... announced that it will hold a conference call and ... 8:30 a.m. EST to discuss its third quarter 2014 ... access the conference call by dialing (888) 347-1165 for ... conference call will be webcast live under the investor ...
(Date:10/27/2014)... 27, 2014 The Italian ... exhibit and sell its artificial "lower limb", after ... patent.      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ... fighting, the definitive judgement has arrived: Roadrunnerfoot, the ... and accessible hi-tech prostheses with composite materials, has ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... Spherix Incorporated (NASDAQ: SPEX ) – ... syndrome and atherosclerosis, and provider of technical and regulatory ... today announced that it has entered into definitive agreements ... stock and warrants to purchase shares of its common ...
... +49(0)69-2222-34066 France: +33(0)1-70-48-01-63 U.K.: +44(0)20-7660-0009 ... is 5634610; to view the webcast, log onto: ... March 13, 2012 - Annual press conference in Goettingen, Germany ... Germany April 24, 2012 - Publication of first-quarter ...
... A relatively fast, easy and inexpensive technique for ... self-assemble into one-, two- and even three-dimensional macroscopic ... researchers with the U.S. Department of Energy (DOE),s ... should enable more effective use of nanorods in ...
Cached Biology Technology:Spherix Announces Registered Direct Offering of $1.15 Million 2Spherix Announces Registered Direct Offering of $1.15 Million 3Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30% 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 2Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 3Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks 4
(Date:10/31/2014)... In the war against Ebola one important hurdle has ... Researchers at the University of North Carolina at Chapel ... of mice that can be infected with Ebola and ... work, published in the current issue of Science ... and vaccines, which are desperately needed to curb the ...
(Date:10/31/2014)...  HITLAB SM , a healthcare innovation and ... HITLAB Innovators Summit SM on December 1, ... partner with the Clinton Foundation,s Health Matters Initiative, ... Business School Alumni Club of New ... Operations Research, bringing together leaders in healthcare and ...
(Date:10/30/2014)... in German . ... fellow humans to behave socially? This is one of ... theory. Previous studies assumed that it is almost impossible ... the Max Planck Institute for Evolutionary Biology have now ... on the cooperative behaviour of others. However, the possibilities ...
Breaking Biology News(10 mins):Improved mouse model will accelerate research on potential Ebola vaccines, treatments 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4
... This press release is available in German . ... pathogens and rogue cells in the body and put them out ... migrate from there into the thymus. Here, they mature and differentiate ... Institute of Immunobiology and Epigenetics in Freiburg have now succeeded for ...
... Deepwater Horizon oil spill in the Gulf of Mexico in April ... fisheries. A new study published in the Canadian Journal of ... 7 years this oil spill could have a $US8.7 billion impact ... in revenue, profit, and wages, and close to 22 000 jobs ...
... The understanding of diseases such as Parkinson,s and Alzheimer,s ... technology at which will enable cell analysis using automated ... School of Information Communication Technology and the Eskitis Institute ... the automated identification, separation and analysis of cells as ...
Cached Biology News:Live from the thymus: T-cells on the move 2Live from the thymus: T-cells on the move 3
... DNA Polymerase I Large (Klenow) Fragment, Exonuclease ... lacks both the 5´→3´ and the 3´→5´ ... DNA Polymerase I (1,2). It is used ... strand displacement amplification (5). Klenow Fragment, Exonuclease ...
SMVT (N-14)...
...
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is a ... effective in inhibiting retroviral activity. Immunogen: ... Specificity: The specificity of the ... of the moles of ddC to moles of ...
Biology Products: